Management of cardiovascular risk in diabetic patients: Evolution or revolution?

Diabetes, Nutrition and Metabolism - Clinical and Experimental

Volumn 15, Issue 2, 2002, Pages 121-127

  Ceriello, A ^a   Sechi, L A ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Cardiovacular disease; Diabetes; Management; Polypharmacy

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; METFORMIN;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COST BENEFIT ANALYSIS; DIET THERAPY; DISEASE ASSOCIATION; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; LIFESTYLE; MEDICAL ETHICS; MEDICAL RESEARCH; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYPHARMACY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; REVIEW; RISK FACTOR; RISK MANAGEMENT; SOCIOECONOMICS; THROMBOSIS; UNITED KINGDOM; DIABETES MELLITUS; HUMAN;

CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DIABETES MELLITUS; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; QUALITY OF LIFE; RISK FACTORS; DIABETES COMPLICATIONS; HUMANS; HYPERLIPIDEMIAS;

EID: 0036105295     PISSN: 03943402     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus
2. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial
3. Coagulation activation in diabetes mellitus: The role of hyperglycemia and therapeutic prospects
4. Hyperglycemia and cardiovascular disease in type 2 diabetes
5. Epidemiology of diabetic dyslipidemia
6. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
7. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol
8. Report of the expert committee on the diagnosis and classification of diabetes mellitus
9. Reduced coronary events in simvastatin-treated subjects with coronary heart disease and diabetes or impaired fasting glucose: Subgroup analyses in the Scandinavian Simvastatin Survival Study (4S)
10. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the Cholesterol and Recurrent Events (CARE) Trial
11. Some aspects of hypertension in diabetes mellitus
12. Intensive blood pressure/glucose control in type 2 diabetes: Why is it so difficult to decrease coronary heart disease?
13. Diabetes and cardiovascular risk factors: The Framingham Study
14. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
15. Effects of calcium channel blockade in older patients with diabetes and systolic hypertension
16. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
17. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
18. Thromboxane biosynthesis and platelet function in type II diabetes mellitus
19. Aspirin as an antiplatelet drug
20. Collaborative overview of randomised trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
21. Aspirin therapy in diabetes
22. Position Statement. Aspirin therapy in diabetes
23. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects
24. Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: A 15-year follow-up from the time of diagnosis
25. NID-DM and its metabolic control predict coronary heart disease in elderly subjects
26. Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects
27. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
28. The relationship between glucose and incident cardiovascular events: A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years
29. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria
30. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study
31. The emerging role of post-prandial hyperglycemic spikes in the pathogenesis of diabetic complications
32. The absence of a glycemic threshold for the development of long-term complications: The perspective of the Diabetes Control and Complications Trial
33. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
34. Is there a glycemic threshold for mortality risk?
35. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study
36. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
37. The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: Implications for the prevention of coronary heart disease
38. Management of dyslipidemia in adults with diabetes
39. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
40. Intensified multifactorial intervention in patient with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study
41. Diabetes Mellitus: A major risk factor for cardiovascular disease
42. Glycemic control with diet, sulfonilurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49)
43. A randomised double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UK Prospective Diabetes Study 44)
44. International Society Hypertension: Guidelines for the management of hypertension
45. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
46. Model of complications of NIDDM. II Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia
47. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: Economic analysis alongside randomised controlled trial (UKPDS 41)
48. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40
49. Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study
50. The cost-effectiveness of lipid lowering in patients with diabetes: Results from the 4S trial
51. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37)
52. Meal-generated oxidative stress in diabetes: The protective effect of red wine
53. Red wine protects diabetic patients from meal-induced oxidative stress and thrombosis activation. A pleasant approach to the prevention of diabetic complications